Jodłowska Elżbieta, Czepczyński Rafał, Wyszomirska Anna, Jarząbek Grażyna, Kędzia Witold, Ruchała Marek
Department of Endocrinology and Metabolism, Poznan University of Medical Sciences, Poznan, Poland.
Department of Gynecology, Poznan University of Medical Sciences, Poznan, Poland.
Contemp Oncol (Pozn). 2016;20(1):8-12. doi: 10.5114/wo.2016.58496. Epub 2016 Mar 16.
Positron emission tomography with computed tomography (PET/CT) is gaining popularity as a method for overall staging assessment of breast cancer. Currently, it is not a part of the routine workup before the beginning of treatment, because of insufficient sensitivity for the detection of small tumors (due to its limited spatial resolution), the heterogeneity of radiotracer uptake by the primary tumor, and unsatisfactory sensitivity in detection of lymph node metastases (particularly when they are small). Nevertheless, it should be considered when there is a high risk of metastases, because then initial PET/CT examination allows for accurate staging and may change the treatment algorithm in up to almost 50% of stage III patients, due to detection of distant and lymph node metastases throughout the whole body. Despite the discussed limitations of PET/CT, there is ongoing research concerning the recommendations for the examination prior to treatment. For a particular group of patients with high risk of metastases, PET/CT may be expected to become a part of the routine workup as the most appropriate staging method.
正电子发射断层扫描与计算机断层扫描（PET/CT）作为一种用于乳腺癌整体分期评估的方法正越来越受到欢迎。目前，它并非治疗开始前常规检查的一部分，原因在于其对小肿瘤检测的敏感性不足（因其空间分辨率有限）、原发肿瘤对放射性示踪剂摄取的异质性以及检测淋巴结转移时的敏感性不尽人意（尤其是当淋巴结较小时）。然而，当转移风险较高时应考虑使用PET/CT，因为此时初始的PET/CT检查能够实现准确分期，并且由于能检测出全身的远处和淋巴结转移，在近50%的III期患者中可能会改变治疗方案。尽管PET/CT存在上述局限性，但关于治疗前检查的建议仍在持续研究中。对于特定的高转移风险患者群体，PET/CT有望成为最适宜的分期方法并纳入常规检查。
